Equities Analysts Issue Forecasts for AVXL Q1 Earnings

Anavex Life Sciences Corp. (NASDAQ:AVXL) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Anavex Life Sciences in a note issued to investors on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju expects that the biotechnology company will earn ($0.18) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $42.00 target price on the stock. The consensus estimate for Anavex Life Sciences’ current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Anavex Life Sciences’ Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.66) EPS.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03.

Separately, D. Boral Capital reissued a “buy” rating and set a $46.00 price objective on shares of Anavex Life Sciences in a report on Wednesday, February 12th.

Anavex Life Sciences Stock Performance

Shares of NASDAQ AVXL opened at $8.70 on Wednesday. The firm has a market cap of $737.93 million, a price-to-earnings ratio of -16.73 and a beta of 0.69. The business’s 50-day simple moving average is $9.96 and its 200-day simple moving average is $7.76. Anavex Life Sciences has a 52 week low of $3.25 and a 52 week high of $14.44.

Institutional Trading of Anavex Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its holdings in Anavex Life Sciences by 2.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock valued at $10,699,000 after buying an additional 51,946 shares during the last quarter. Nwam LLC lifted its position in shares of Anavex Life Sciences by 0.3% in the 4th quarter. Nwam LLC now owns 913,051 shares of the biotechnology company’s stock worth $9,806,000 after acquiring an additional 2,575 shares during the period. Northern Trust Corp lifted its position in shares of Anavex Life Sciences by 1.6% in the 4th quarter. Northern Trust Corp now owns 706,901 shares of the biotechnology company’s stock worth $7,592,000 after acquiring an additional 10,938 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Anavex Life Sciences by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 677,215 shares of the biotechnology company’s stock worth $7,273,000 after acquiring an additional 11,239 shares during the period. Finally, Invesco Ltd. lifted its position in shares of Anavex Life Sciences by 2,419.8% during the 4th quarter. Invesco Ltd. now owns 615,048 shares of the biotechnology company’s stock worth $6,606,000 after buying an additional 590,639 shares during the period. Institutional investors and hedge funds own 31.55% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.